Clinical trials of targeted toxins

Arthur E. Frankel, Edward P. Tagge, Mark C. Willingham

Research output: Contribution to journalArticlepeer-review

61 Scopus citations

Abstract

Immunotoxins (monoclonal antibodies chemically coupled to peptide toxins) and fusion toxins (peptide ligands fused genetically to peptide toxins) have been used to treat a variety of malignancies over the last 20 years. Problems with normal tissue toxicities (vascular leak syndrome, hepatotoxicity, and neurotoxicities), poor penetration to tumor interstitum, and humoral immune responses have limited clinical efficacy. Higher response rates were observed with systemic therapy of leukemias and lymphomas and regional therapy of primary brain tumors. Ongoing studies are examining the role of targeted toxins in combination with chemoradiotherapy and in minimal residual disease settings.

Original languageEnglish (US)
Pages (from-to)307-317
Number of pages11
JournalSeminars in Cancer Biology
Volume6
Issue number5
DOIs
StatePublished - Jan 1 1995

Keywords

  • Diphtheria toxin
  • Fusion toxins
  • Immunotoxins
  • Pokeweed antiviral protein
  • Pseudomonas exotoxin
  • Ricin
  • Saporin

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical trials of targeted toxins'. Together they form a unique fingerprint.

Cite this